SOPHiA GENETICS SA (NASDAQ:SOPH) Shares Sold by Millennium Management LLC

Millennium Management LLC decreased its stake in SOPHiA GENETICS SA (NASDAQ:SOPHFree Report) by 63.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 662,656 shares of the company’s stock after selling 1,158,816 shares during the period. Millennium Management LLC owned 1.01% of SOPHiA GENETICS worth $3,035,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its holdings in shares of SOPHiA GENETICS by 1.2% in the 1st quarter. Principal Financial Group Inc. now owns 1,007,177 shares of the company’s stock worth $4,965,000 after acquiring an additional 11,677 shares during the last quarter. Moloney Securities Asset Management LLC grew its stake in shares of SOPHiA GENETICS by 111.4% in the 1st quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after purchasing an additional 93,800 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of SOPHiA GENETICS by 112.1% in the 1st quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock worth $1,296,000 after acquiring an additional 138,933 shares in the last quarter. Edmond DE Rothschild Holding S.A. lifted its holdings in SOPHiA GENETICS by 5.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock worth $1,002,000 after buying an additional 9,700 shares in the last quarter. Finally, Akre Capital Management LLC acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $1,418,000. Institutional investors own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SOPH. Morgan Stanley cut SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $10.00 to $5.00 in a report on Wednesday, August 7th. Royal Bank of Canada decreased their target price on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, Guggenheim assumed coverage on shares of SOPHiA GENETICS in a report on Thursday, June 27th. They set a “buy” rating and a $6.00 price target on the stock.

Get Our Latest Research Report on SOPHiA GENETICS

SOPHiA GENETICS Stock Down 3.6 %

SOPH opened at $3.39 on Tuesday. The stock has a market cap of $221.29 million, a price-to-earnings ratio of -3.02 and a beta of 1.03. The company has a quick ratio of 4.17, a current ratio of 4.40 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $3.67 and its two-hundred day moving average price is $4.40. SOPHiA GENETICS SA has a twelve month low of $2.70 and a twelve month high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPHGet Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. The company had revenue of $15.81 million for the quarter, compared to analysts’ expectations of $17.58 million. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. During the same quarter last year, the company earned ($0.33) EPS. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.95 earnings per share for the current year.

SOPHiA GENETICS Profile

(Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

Recommended Stories

Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPHFree Report).

Institutional Ownership by Quarter for SOPHiA GENETICS (NASDAQ:SOPH)

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.